The challenges of bacteriophage therapy

Industrial Pharmacy

Volumn , Issue 31, 2011, Pages 14-18

  Sulakvelidze, Alexander ^a  

^a Intralytix Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BACTERIAL DNA; PENICILLIN G; PROBIOTIC AGENT;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL INFECTION; BACTERIAL STRAIN; BACTERIOPHAGE; DRUG LEGISLATION; DRUG MARKETING; DRUG MECHANISM; DRUG SAFETY; DRUG SYNTHESIS; ECOSYSTEM; ENVIRONMENT; FOOD AND DRUG ADMINISTRATION; HOSPITAL PHARMACY; HOST; MICROBIAL COMMUNITY; MOLECULAR WEIGHT; NONHUMAN; PREVALENCE; SAFETY;

EID: 84859026401     PISSN: 17414911     EISSN: None     Source Type: Trade Journal    
DOI: None     Document Type: Article

References (7)

1. Summers WC. Bacteriophage discovered. Felix d'Herelle and the origins of molecular biology. New Haven, CT: Yale University Press; 1999. p. 47-59.
2. Duckworth DH. Who discovered bacteriophage?. Bacteriol Rev. 1976 Dec;40(4):793-802.
3. Chain E, Florey HW, Gardner AD, Heatley NG, Jennings MA, Orr-Ewing J, et al. Penicillin as chemotherapeutic agent. Lancet. 1940;2:226.
4. Summers WC. The hope of phage therapy. Felix d'Herelle and the origins of molecular biology. New Haven, CT: Yale University Press; 1999. p. 108-24.
5. Bruynoghe R, Maisin J. Essais de thérapeutique au moyen du bactériophage du Staphylocoque. J Compt Rend Soc Biol. 1921;85:1120-1.
6. Moody EE, Trousdale MD, Jorgensen JH, Shelokov A. Bacteriophages and endotoxin in licensed live-virus vaccines. J Infect Dis. 1975 May;131(5):588-91.
7. Wolcott R, Rhoads D, Kuskowski M, Ward L, Sulakvelidze A. Bacteriophage therapy of venous leg ulcers in humans: results of a Phase I safety trial. Journal of Wound Care. 2009;18(6):237-43.